acyclovir
enabl
first
system
antivir
therapi
mani
antivir
agent
subsequ
develop
acyclovir
target
herp
simplex
viru
varicellazost
infect
individu
antivir
agent
target
one
viral
infect
caus
one
viru
two
virus
famili
elion
shiraki
shiraki
among
antivir
agent
one
uniqu
featur
favipiravir
broad
spectrum
activ
toward
rna
virus
includ
influenza
viru
rhinoviru
respiratori
syncyti
viru
dna
virus
shown
fig
furuta
et
al
furuta
et
al
favipiravir
show
better
efficaci
treat
influenza
infect
oseltamivir
tamiflu
takahashi
et
al
tanaka
et
al
efficaci
treat
pathogen
avian
influenza
oseltamivirresist
virus
confirm
anim
kiso
et
al
sidwel
et
al
clinic
trial
treatment
season
influenza
perform
japan
us
favipiravir
approv
treatment
novel
reemerg
influenza
virus
japan
favipiravir
consid
administr
patient
govern
judg
drug
use
countermeasur
novel
reemerg
influenza
virus
japanes
govern
taiwanes
center
diseas
control
cdc
decid
stockpil
favipiravir
peopl
countermeasur
sever
influenza
favipiravir
submit
addit
indic
sever
fever
thrombocytopenia
syndrom
sft
base
clinic
trial
yasukawa
addit
influenza
japan
favipiravir
highlight
treatment
lethal
ebola
viru
epidem
west
africa
standard
treatment
lethal
ebola
viru
infect
avail
favipiravir
report
effect
prophylaxi
treat
lethal
ebola
viru
infect
anim
model
oestereich
et
al
smither
et
al
licens
influenza
treatment
base
confirm
safeti
efficaci
clinic
trial
human
base
inform
favipiravir
success
use
postexposur
prophylaxi
treatment
patient
ebola
viru
infect
bai
et
al
jacob
et
al
sissoko
et
al
sinc
children
die
avian
influenza
hong
kong
ku
chan
concern
regard
novel
influenza
pandem
note
one
immun
virus
novel
influenza
strain
caus
sever
diseas
particularli
pneumonia
season
influenza
mortal
rate
influenza
lai
et
al
influenza
li
et
al
combin
therapi
oseltamivir
use
treat
patient
sever
influenza
china
cao
wang
et
al
although
novel
influenza
strain
current
occur
sporad
research
concern
possibl
pandem
review
describ
specif
featur
favipiravir
mechan
action
fact
favipiravir
alon
produc
resist
virus
among
antiinfluenza
drug
outstand
featur
favipiravir
among
antiinfluenza
drug
expect
play
central
role
treatment
lethal
influenza
pandem
sever
rna
viru
infect
standard
treatment
unavail
help
clinician
scientist
policymak
consid
prepared
strategi
new
influenza
pandem
prevent
vaccin
develop
joint
develop
project
toyama
chemic
co
ltd
initi
develop
antiherp
drug
screen
identifi
sever
promis
compound
efficaci
exceed
efficaci
acyclovir
anim
approxim
compound
synthes
compani
screen
activ
requir
categori
drug
antivir
antibacteri
antiinflammatori
nervou
system
agent
regard
favipiravir
one
compound
show
antiinfluenza
viru
activ
optim
activ
efficaci
anim
experi
yield
code
number
favipiravir
b
guanosin
inosin
aicar
ribavirin
ribosyl
favipiravir
guanosin
inosin
aicar
biosynthes
bodi
ribavirin
ribosyl
favipiravir
synthes
nucleosid
analogu
similar
chemic
structur
favipiravir
two
compound
differ
contain
pyrazin
triazol
imidazol
mark
red
circl
favipiravir
laboratori
conduct
drug
efficaci
valid
test
infect
mice
ferret
conduct
experi
compar
efficaci
favipiravir
oseltamivir
tamiflu
base
chemic
structur
favipiravir
inhibit
rna
synthesi
laboratori
tri
isol
resist
viru
lack
gener
resist
virus
investig
clinic
trial
treatment
season
influenza
perform
japan
us
favipiravir
approv
treatment
novel
reemerg
influenza
virus
japan
howev
favipiravir
consid
administr
patient
govern
judg
drug
use
countermeasur
novel
reemerg
influenza
virus
addit
favipiravir
contraind
use
pregnant
women
exert
teratogen
embryotox
effect
anim
taiwanes
cdc
decid
stockpil
favipiravir
peopl
becam
infect
new
strain
influenza
includ
avian
swine
influenza
japanes
govern
decid
stockpil
favipiravir
novel
influenza
countermeasur
million
peopl
recent
clinic
trial
perform
assess
efficaci
treat
sft
japan
yasukawa
combin
therapi
oseltamivir
treat
patient
sever
influenza
china
cao
wang
et
al
addit
influenza
favipiravir
submit
addit
indic
sft
japan
base
clinic
trial
indic
outstand
featur
broad
spectrum
antirna
viru
drug
compound
first
show
antiinfluenza
activ
obtain
screen
antivir
drug
target
influenza
favipiravir
optim
term
activ
stabil
anim
dr
shiraki
k
suggest
chemic
structur
activ
compound
deriv
includ
favipiravir
resembl
nucleosid
analogu
presum
mechan
action
inhibit
rna
synthesi
fig
three
compound
aicar
biosynthes
de
novo
amino
acid
ribosylfavipiravir
ribavirin
similar
chemic
structur
suggest
favipiravir
function
purin
homologu
inhibit
viral
rna
synthesi
therefor
dr
shiraki
k
suggest
synthesi
ribosyl
form
favipiravir
better
efficaci
ribosyl
favipiravir
improv
antivir
activ
addit
effect
concentr
plaqu
reduct
ec
adenin
guanin
adenosin
guanosin
inosin
assay
medium
abolish
antiinfluenza
viru
activ
favipiravir
furuta
et
al
base
find
favipiravir
mainli
incorpor
salvag
pathway
purin
nucleotid
purin
phosphoribosyltransferas
craig
eakin
phosphoryl
favipiravirtriphosph
substrat
viral
rnadepend
rna
polymeras
rdrp
phosphoryl
favipiravir
hypoxanthin
guanin
phosphoribosyltransferas
confirm
subsequ
studi
naesen
et
al
favipiravir
show
antiinfluenza
viru
activ
toward
subtyp
season
influenza
viru
strain
includ
type
b
c
laboratori
strain
clinic
isol
well
oseltamivirresist
viru
ec
rang
furuta
et
al
although
effect
influenza
virus
cell
cultur
level
confirm
use
favipiravir
antiinfluenza
drug
confirm
analyz
efficaci
anim
model
influenza
infect
describ
led
drug
develop
favipiravir
effect
rna
virus
polioviru
rhinoviru
respiratori
syncyti
viru
effect
dna
virus
herp
simplex
cytomegaloviru
adenoviru
furuta
et
al
base
antivir
activ
toward
four
rna
virus
expect
favipiravir
activ
broad
rang
rna
virus
favipiravir
evalu
develop
broad
spectrum
antirna
viru
drug
includ
lethal
rna
viru
infect
antirna
viru
activ
favipiravir
analyz
cellular
level
efficaci
studi
perform
anim
model
human
lethal
rna
viru
infect
shown
tabl
patient
ebola
viru
infect
west
africa
patient
rna
viru
infect
treat
favipiravir
base
efficaci
human
lethal
rna
viru
infect
clinic
experi
efficaci
patient
season
influenza
licensur
human
use
identifi
two
antipyret
step
influenza
infect
shown
fig
influenza
infect
replic
epithelium
upper
respiratori
tract
induc
product
interferon
ifn
cytokin
induc
cyclooxygenas
express
prostaglandin
e
product
caus
fever
effect
interferon
interleukin
il
determin
neutral
action
intraven
inject
respect
antibodi
influenzainfect
mice
kurokawa
watanab
shimizu
sawamura
shiraki
effect
aspirin
nsaid
cinnamyl
compound
deriv
herbal
extract
influenzainfect
mice
mous
macrophagederiv
cell
determin
cinnamyl
compound
show
compoundspecif
respons
fever
increas
level
influenzainfect
mice
cinnamyl
compound
regul
cytokin
level
modul
amount
kurokawa
brown
kagawa
shiraki
cinnamyl
compound
clarithromycin
increas
level
day
day
bronchoalveolar
fluid
mice
decreas
area
pneumonia
throughout
lung
role
day
confirm
direct
nasal
applic
nasal
administr
reduc
viru
yield
bronchoalveolar
fluid
influenzainfect
mice
hama
et
al
kurokawa
tsurita
brown
fukuda
shiraki
tsurita
et
al
cinnamyl
compound
mainli
deriv
medicin
herb
prevent
induct
fever
influenzainfect
mice
decreas
serum
level
contrast
aspirin
suppress
fever
inhibit
hypothalam
cyclooxygenas
activ
prostaglandin
e
product
without
affect
high
level
kurokawa
imakita
kumeda
yukawa
shiraki
kurokawa
kumeda
yamamura
kamiyama
shiraki
determin
two
step
antipyret
action
cinnamyl
compound
nsaid
fever
cascad
influenza
infect
studi
efficaci
favipiravir
influenza
anim
perform
biosafeti
level
laboratori
steril
pyrogenfre
distil
water
inject
use
drink
ensur
traceabl
experi
conduct
pharmacolog
studi
famciclovir
approv
applic
japan
efficaci
valid
studi
favipiravir
conduct
mice
ferret
use
influenza
infect
system
describ
laboratori
sinc
laboratori
establish
influenza
infect
model
investig
cytokin
cascad
induc
fever
influenza
virusinfect
anim
perform
virolog
analysi
examin
effect
crude
drug
pathogenesi
cytokin
level
well
antivir
activ
kurokawa
et
al
kurokawa
kumeda
yamamura
kamiyama
shiraki
tsurita
et
al
anim
model
influenza
use
studi
efficaci
favipiravir
influenzainfect
anim
favipiravir
effect
cell
cultur
effect
anim
infect
influenza
viru
must
confirm
first
observ
prevent
lethal
influenza
infect
oral
administr
favipiravir
significantli
effect
allevi
influenza
infect
mice
furuta
et
al
efficaci
character
variou
condit
convinc
favipiravir
develop
influenza
drug
human
confirm
therapeut
activ
two
speci
anim
mice
ferret
infect
influenza
viru
fig
show
one
comparison
efficaci
favipiravir
oseltamivir
influenza
viru
infect
model
establish
high
titer
viru
seri
experi
better
efficaci
favipiravir
compar
oseltamivir
observ
anim
sever
lethal
influenza
infect
high
viral
load
takahashi
et
al
favipiravir
oseltamivir
show
similar
efficaci
lowdos
infect
efficaci
favipiravir
influenza
drug
clearli
increas
compar
oseltamivir
hightit
viru
infect
fig
mice
control
group
die
day
highdos
infect
oseltamivir
treatment
prolong
surviv
period
three
day
prevent
death
favipiravir
treatment
cure
lethal
infect
mice
surviv
favipiravir
exhibit
better
efficaci
oseltamivir
delay
administr
begin
h
infect
season
influenza
takahashi
et
al
mice
infect
low
titer
repres
nonleth
infect
model
consid
correspond
human
season
infect
model
model
oseltamivir
favipiravir
equal
effect
differ
efficaci
despit
differ
mechan
action
hightit
infect
repres
lethal
infect
model
consid
correspond
novel
influenza
infect
human
although
oseltamivir
ineffect
model
favipiravir
effect
improv
surviv
case
indic
import
administ
drug
mechan
action
reduc
viral
load
tabl
therapeut
activ
favipiravir
human
rna
viru
infect
anim
model
human
rna
viru
infect
aria
et
al
bixler
et
al
carolin
et
al
escribanoromero
et
al
gowen
westov
miao
et
al
gowen
westov
sefe
et
al
gowen
et
al
gowen
et
al
hawman
et
al
jochman
et
al
juland
shafer
et
al
mendenhal
et
al
morrey
et
al
oestereich
et
al
oestereich
rieger
et
al
safronetz
et
al
safronetz
et
al
scharton
et
al
tani
et
al
westov
et
al
yamada
et
al
zhu
et
al
refer
favipiravir
use
human
underlin
mortal
rate
deriv
world
health
organ
b
cdc
c
pan
american
health
organ
paho
western
equin
enceph
spickler
e
argentin
hemorrhag
fever
viru
infect
enria
maiztegui
product
induc
recognit
singlestrand
rna
doublestrand
rna
influenza
viru
genom
tolllik
yang
chen
diebold
et
al
guillot
et
al
poux
et
al
wong
et
al
respect
infect
cell
influenza
infect
induc
product
mous
macrophagederiv
cell
suppress
effect
favipiravir
oseltamivir
compar
cellbas
system
favipiravir
significantli
suppress
product
influenza
virusinfect
cell
compar
activ
form
oseltamivir
tanaka
et
al
appear
first
disappear
first
cell
among
kurokawa
et
al
observ
signific
reduct
level
cell
influenzainfect
mice
treat
favipiravir
antivir
activ
favipiravir
attribut
decreas
pulmonari
viral
load
level
airway
influenza
virusinfect
mice
compar
oseltamivir
reduct
viral
rna
load
induc
favipiravir
might
result
reduct
product
allevi
lung
pathogenesi
damjanov
et
al
tanaka
et
al
base
find
intracellular
viral
rna
less
recogn
intracellular
tolllik
receptor
result
decreas
product
inflammatori
cytokin
mechan
may
also
contribut
enhanc
effect
favipiravir
treatment
allevi
influenza
infect
compar
oseltamivir
treatment
favipiravir
display
superior
properti
oseltamivir
mous
model
confirm
efficaci
influenzainfect
mice
ferret
confirm
efficaci
drug
two
speci
anim
convinc
us
efficaci
human
possibl
use
standard
treatment
choic
influenza
futur
fig
show
influenza
viru
growth
cycl
site
action
antiinfluenza
drug
viral
hemagglutinin
bind
sialic
acid
cell
surfac
viral
particl
incorpor
endosom
endosom
acidifi
ph
decreas
valu
characterist
late
endosom
structur
hemagglutinin
chang
process
mediat
ion
channel
endosom
membran
viral
envelop
fuse
viral
genom
viral
particl
releas
cytoplasm
uncoat
viral
genom
rdrp
complex
transport
nucleu
transcript
replic
viral
rna
synthesi
begin
synthes
rna
contain
cap
structur
requir
mrna
cap
structur
host
mrna
excis
transfer
viral
rna
capdepend
endonucleas
viral
rdrp
complex
result
format
viral
mrna
capsnatch
viral
mrna
produc
viral
protein
translat
viral
protein
rdrprna
complex
form
viral
particl
subsequ
bud
cell
membran
hemagglutinin
viral
particl
bud
cell
surfac
bind
sialic
acid
surfac
infect
cell
viral
particl
releas
infect
cell
cleavag
sialic
acid
viral
neuraminidas
na
next
round
infect
amantadin
inhibit
uncoat
influenza
late
endosom
viral
rna
replic
infect
cell
amantadin
inhibit
influenza
b
howev
influenza
viru
becom
fig
cascad
fever
induct
influenza
antipyret
action
cinnamyl
compound
nsaid
influenza
infect
induc
interferon
ifn
product
subsequ
induc
interleukin
il
product
act
hypothalamu
next
cyclooxygenas
express
induc
prostaglandin
pg
e
product
gener
fever
cinnamyl
compound
medicin
herb
antiifn
antibodi
antibodi
nonsteroid
antiinflammatori
drug
nsaid
aspirin
act
step
process
cinnamyl
compound
nsaid
inhibit
induct
ifn
cyclooxygenas
activ
respect
fever
cascad
work
antipyret
influenza
regard
pneumonia
product
induc
bronchoalveolar
fluid
balf
second
third
day
infect
respect
increas
level
reduc
viral
load
balf
area
pneumonia
throughout
lung
resist
even
epidem
occur
close
facil
current
influenza
virus
suscept
amantadin
favipiravir
inhibit
viral
rna
synthesi
therefor
viral
rna
produc
infect
cell
na
inhibitor
nai
zanamivir
oseltamivir
peramivir
laminamivir
inhibit
na
activ
viral
particl
surfac
infect
cell
releas
viral
particl
cell
surfac
cell
next
round
infect
nai
result
accumul
viral
particl
cell
surfac
inhibit
spread
viru
infect
nai
current
main
choic
antiinfluenza
drug
baloxavir
marboxil
baloxavir
select
inhibitor
influenza
capdepend
endonucleas
viral
rdrp
complex
baloxavir
inhibit
mrna
synthesi
subsequ
viral
protein
synthesi
genom
rna
without
cap
structur
synthes
incorpor
rdrpviral
rna
complex
presenc
baloxavir
favipiravir
inhibit
viral
rna
synthesi
chain
termin
inhibit
genom
rna
synthesi
import
differ
antiinfluenza
drug
substanti
form
pool
genom
rna
contain
drugresist
mutant
synthes
viral
rdrp
low
fidel
rdrpviral
rna
complex
antiinfluenza
drug
nai
baloxavir
inhibit
spread
infect
allow
synthesi
genom
rna
genom
rna
pool
import
perspect
gener
resist
virus
sourc
drugresist
virus
spontan
mutat
rate
influenza
viru
rdrp
complex
approxim
titer
influenza
viru
cultur
reach
approxim
plaqu
form
unitsml
ml
cm
flask
genom
contain
approxim
base
indic
probabl
alter
per
nucleotid
genom
therefor
type
mutat
genom
synthes
present
genom
rna
even
cell
treat
antiinfluenza
drug
high
probabl
resist
viru
alreadi
present
viru
grew
rapidli
larg
quantiti
start
treatment
addit
viral
rna
form
cell
patient
treat
antiinfluenza
drug
serv
sourc
drugresist
virus
subsequ
drugresist
influenza
virus
appear
readili
mutant
genom
rna
pool
drug
treatment
fig
replic
cycl
influenza
site
action
antiinfluenza
drug
influenza
viru
hemagglutinin
ha
bind
receptor
sialic
acid
cell
surfac
taken
endosom
endocytosi
endosom
gradual
acidifi
produc
late
endosom
viral
ion
channel
acidifi
viral
particl
structur
trimer
ha
molecul
chang
show
membran
fusion
activ
endosom
membran
envelop
fuse
genom
rna
rdrp
complex
viru
particl
releas
cytoplasm
uncoat
transport
nucleu
cytoplasm
transcript
replic
genom
rna
rdrp
complex
occur
nucleu
genom
rna
abundantli
produc
genom
rna
lack
cap
structur
requir
mrna
function
cap
portion
host
mrna
remov
capdepend
endonucleas
cap
portion
coupl
genom
rna
viral
mrna
synthesi
complet
capsnatch
viral
protein
synthes
mrna
viral
protein
genom
rna
transport
cell
surfac
bud
membran
form
viral
particl
sinc
bud
viru
bound
sialic
acid
infect
cell
surfac
via
ha
protein
viru
particl
unabl
leav
infect
cell
infect
new
cell
reason
sialic
acidha
bond
cleav
neuraminidas
na
surfac
viru
particl
viru
particl
releas
surfac
infect
cell
proce
next
round
infect
amantadin
block
uncoat
inhibit
acidif
mediat
protein
viru
particl
late
endosom
thu
infect
unabl
complet
favipiravir
inhibit
viral
rna
synthesi
termin
chain
elong
incorpor
site
new
rna
gener
cell
baloxavir
marboxil
prevent
capsnatch
viral
mrna
produc
result
failur
produc
viral
protein
infecti
virus
genom
rna
synthes
remain
cell
na
inhibitor
block
cleavag
sialic
acidha
bond
viru
surfac
infect
cell
prevent
spread
viral
infect
na
inhibitor
allow
genom
rna
synthesi
favipiravir
inhibit
viral
rna
synthesi
baloxavir
nai
allow
viral
rna
synthesi
although
viral
spread
inhibit
baloxavir
nai
viral
rna
synthes
pool
genom
rna
serv
rich
sourc
resist
virus
replic
cycl
influenza
virus
approxim
h
entri
product
new
viru
robust
growth
begin
infect
rate
four
replic
cycl
per
day
cours
influenza
viru
infect
analyz
differ
studi
healthi
particip
experiment
influenza
viru
infect
carrat
et
al
infect
result
substanti
increas
viral
shed
first
day
experiment
influenza
viru
infect
reach
maximum
valu
second
day
fever
report
infect
individu
system
symptom
fever
muscl
ach
fatigu
headach
peak
earlier
day
inocul
resolv
faster
respiratori
nasal
symptom
presenc
preexist
antibodi
modifi
mean
durat
ill
day
particip
prehemagglutinin
inhibit
titer
compar
day
particip
prehemagglutinin
inhibit
titer
inocul
wildtyp
viru
doyl
et
al
influenza
caus
dri
cough
fever
headach
immunocompromis
patient
exhibit
significantli
longer
length
ill
delay
viru
clearanc
memoli
et
al
mean
durat
viral
shed
immunocompromis
nonimmunocompromis
patient
day
median
valu
day
respect
indic
viral
replic
persist
week
disappear
major
symptom
preexist
immun
immunocompet
import
modifi
sever
symptom
influenza
season
influenza
strain
adapt
human
includ
b
influenza
caus
season
epidem
influenza
among
human
everi
year
season
influenza
virus
mainli
infect
epithelium
upper
respiratori
tract
hemagglutinin
bind
receptor
sialic
acid
link
galactos
linkag
distribut
upper
respiratori
tract
although
strain
caus
epidem
everi
year
suscept
sever
ill
modifi
degre
immun
host
describ
novel
influenza
deriv
avian
influenza
sourc
concern
caus
influenza
pandem
avian
influenza
divid
highli
pathogen
avian
influenza
lowpathogen
avian
influenza
base
molecular
characterist
viru
abil
caus
diseas
mortal
chicken
lowpathogen
avian
influenza
highli
pathogen
avian
influenza
virus
caus
sever
lethal
infect
human
cdc
sinc
novel
influenza
strain
transmit
origin
host
bird
avian
receptor
sialic
acid
link
galactos
linkag
receptor
distribut
respiratori
bronchiol
alveolar
epitheli
cell
human
shinya
et
al
although
name
influenza
viru
common
season
influenza
novel
influenza
new
subtyp
influenza
caus
sever
influenza
human
complet
new
subtyp
viru
human
neither
histori
infect
immun
season
influenza
mainli
infect
upper
respiratori
tract
novel
influenza
caus
pneumonia
mainli
due
infect
pulmonari
epithelium
furthermor
unlik
presenc
certain
level
immun
season
influenza
immun
exist
novel
influenza
therefor
sever
infect
appear
caus
prolong
viru
growth
period
affin
pulmonari
epithelium
shinya
et
al
describ
novel
influenza
caus
sever
diseas
particularli
pneumonia
compar
season
influenza
mortal
rate
lai
et
al
li
et
al
oseltamivir
nai
treatment
choic
influenza
infect
emerg
resist
viru
day
detect
oseltamivirtr
influenza
ainfect
patient
higher
frequenc
observ
children
age
year
viral
clearanc
occur
day
lina
et
al
overal
incid
oseltamivirresist
viru
whitley
et
al
kiso
et
al
oseltamivirtr
children
oseltamivirresist
influenza
appear
becom
domin
treatment
anoth
concern
preval
oseltamivirresist
strain
observ
season
oseltamivirresist
season
virus
possess
na
substitut
spread
global
us
dharan
et
al
south
africa
oceania
se
asia
hurt
et
al
europ
particular
preval
observ
norway
gradual
increas
observ
europ
approxim
week
week
meijer
et
al
thu
oseltamivirresist
viru
adapt
human
becom
replac
epidem
viru
worldwid
singledos
baloxavir
superior
placebo
allevi
influenza
symptom
oseltamivir
placebo
reduc
viral
load
day
initi
patient
uncompl
influenza
hayden
et
al
emerg
baloxavirresist
mutant
substitut
occur
baloxavir
recipi
phase
phase
trial
respect
patient
substitut
posit
viral
polymeras
acid
protein
baloxavirresist
viru
exhibit
sustain
allevi
viru
clearanc
baloxavirresist
virus
crossresist
favipiravir
oseltamivir
omoto
et
al
baloxavirresist
virus
identifi
day
baloxavirtr
immunocompet
adult
adolesc
uehara
et
al
baloxavirresist
virus
emerg
patient
emerg
associ
prolong
detect
infecti
viru
median
time
h
time
ill
median
vs
h
patient
without
virus
hirotsu
et
al
baloxavirresist
influenza
virus
caus
new
humantohuman
infect
abil
spread
infect
takashita
et
al
oseltamivirand
baloxavirresist
mutant
emerg
becom
domin
virus
treatment
resist
virus
transmit
host
thu
resist
virus
may
becom
domin
pandem
virus
contrast
favipiravir
treatment
chang
suscept
pair
virus
favipiravir
treatment
takashita
et
al
although
number
case
limit
pair
might
suffici
detect
viru
resist
current
antiinfluenza
drug
suggest
favipiravirresist
mutant
appear
favipiravir
alon
may
maintain
efficaci
begin
end
influenza
pandem
without
replac
resist
strain
effect
drug
reduc
treatment
pandem
influenza
pandem
global
outbreak
novel
influenza
viru
pandem
occur
novel
influenza
virus
emerg
abl
infect
peopl
easili
spread
person
person
effici
sustain
manner
two
decad
elaps
sinc
avian
influenza
case
report
hong
kong
decad
elaps
sinc
recent
influenza
pandem
occur
sporad
case
influenza
infect
accumul
must
prepar
strain
novel
influenza
strain
might
progress
influenza
pandem
spread
global
influenza
pandem
caus
sever
pneumonia
gener
drugresist
viru
render
antivir
drug
ineffect
prolong
viral
growth
patient
treat
oseltamivir
baloxavir
although
drugresist
virus
may
reduc
abil
grow
use
drug
mani
patient
continu
select
pressur
ensur
resist
virus
becom
domin
drug
select
continu
resist
strain
becom
domin
pandem
drugresist
strain
select
mani
patient
treat
antiinfluenza
drug
regard
resist
viru
good
replic
capabl
oseltamivirresist
virus
possess
na
substitut
spread
global
season
thu
experi
global
pandem
oseltamivirresist
strain
favipiravir
maintain
efficaci
first
last
patient
pandem
resist
strain
appear
replac
origin
strain
favipiravir
significantli
effect
treat
mice
sever
influenza
infect
character
high
viral
load
oseltamivir
takahashi
et
al
favipiravirresist
viru
emerg
treatment
outstand
featur
favipiravir
antiinfluenza
drug
exploit
treat
patient
sever
influenza
combin
oseltamivir
china
cao
wang
et
al
favipiravir
oseltamivir
combin
therapi
acceler
clinic
recoveri
compar
oseltamivir
monotherapi
sever
influenza
dose
favipiravir
use
studi
mention
mg
twice
day
day
follow
mg
twice
day
day
approv
favipiravir
dose
japan
mg
twice
day
day
follow
mg
twice
day
day
viral
replic
period
day
longer
season
influenza
lina
et
al
memoli
et
al
drug
administr
stop
viru
replic
period
resist
strain
appear
viru
replic
fever
relaps
thu
day
administr
may
requir
sever
influenza
novel
influenza
accord
eurowho
three
influenza
pandem
occur
interv
sever
decad
centuri
sever
socal
spanish
flu
caus
viru
estim
caus
million
death
milder
pandem
occur
subsequ
asian
flu
caus
viru
hong
kong
flu
caus
viru
estim
caus
million
death
case
pandem
mild
global
estim
pandem
caus
death
first
year
alon
elderli
individu
immun
pandem
although
peopl
develop
milder
form
influenza
spread
quickli
throughout
world
avian
influenza
outbreak
occur
peopl
infect
pandem
similar
faster
global
spread
predict
whether
next
pandem
occur
difficult
determin
research
current
concern
strain
high
lethal
strain
adapt
human
becom
pandem
pathogen
may
milder
similar
previou
pandem
influenza
pandem
caus
sever
diseas
may
caus
substanti
damag
human
health
social
dysfunct
need
pandem
countermeasur
import
consider
favipiravir
broad
spectrum
activ
toward
rna
virus
includ
lifethreaten
rna
virus
exhibit
efficaci
anim
model
infect
tabl
summar
efficaci
favipiravir
anim
model
human
infect
base
efficaci
anim
model
use
treat
human
diseas
ebola
viru
infect
bai
et
al
jacob
et
al
sissoko
et
al
lassa
fever
raab
et
al
noroviru
rui
et
al
rabi
baker
notabl
broad
spectrum
antirna
viru
drug
favipiravir
submit
addit
indic
sft
japan
base
clinic
trial
yasukawa
broad
spectrum
activ
favipiravir
toward
rna
virus
review
includ
antirna
viru
activ
vitro
vivo
anim
model
furuta
et
al
furuta
komeno
nakamura
concern
ebola
viru
infect
efficaci
favipiravir
postexposur
prophylaxi
pep
shown
mous
model
smither
et
al
therapeut
mous
model
ebola
viru
diseas
oestereich
ludtk
et
al
treatment
favipiravir
day
lethal
infect
ebola
viru
cure
mice
treatment
start
initi
liver
damag
elev
ast
alt
viru
detect
blood
howev
administr
favipiravir
day
prolong
surviv
four
five
mice
die
liver
damag
viremia
advanc
earli
treatment
favipiravir
effect
diseas
advanc
includ
liver
damag
efficaci
prolong
surviv
limit
one
five
mice
indic
treatment
start
liver
damag
progress
irrevers
level
thu
favipiravir
may
abl
cure
ebola
viru
infect
earli
phase
infect
cur
activ
favipiravir
may
limit
patient
advanc
infect
dose
favipiravir
use
treat
human
ebola
viru
infect
mg
first
day
mgday
day
total
mg
administ
pep
treatment
four
eight
healthcar
worker
includ
two
maximum
risk
exposur
penetr
injuri
freshli
use
hollowbor
needl
administ
pep
favipiravir
alon
favipiravir
antiebola
agent
develop
ebola
viru
diseas
jacob
et
al
although
needl
stick
confirm
result
infect
probabl
infect
high
base
previou
observ
pep
consid
effect
observ
pep
use
mous
model
smither
et
al
ebola
studi
conduct
guinea
includ
patient
analyz
compar
patient
histor
control
group
favipiravir
treatment
reduc
mortal
rate
low
viral
load
group
compar
histor
control
group
treat
favipiravir
reduct
mortal
rate
statist
signific
sissoko
et
al
ebola
studi
conduct
sierra
leon
includ
favipiravirtr
patient
histor
control
patient
overal
surviv
rate
favipiravir
treatment
group
higher
control
group
vs
p
bai
et
al
epidem
ebola
viru
infect
west
africa
patient
treat
without
favipiravir
period
prepar
favipiravir
treatment
classifi
histor
control
therapeut
efficaci
favipiravir
compar
patient
group
treat
favipiravir
histor
patient
group
two
clinic
trial
describ
random
placebocontrol
trial
desir
confirm
therapeut
effect
clinic
trial
placebo
group
ethic
problem
abl
receiv
effect
drug
recov
fatal
infect
anim
model
studi
conduct
compar
effect
favipiravir
treatment
patient
treat
period
prior
start
drug
administr
histor
control
patient
group
treat
favipiravir
clinic
studi
readi
number
patient
limit
favipiravir
use
emerg
compassion
treatment
lassa
fever
noroviru
rabi
case
review
focus
human
administr
term
broad
spectrum
rna
viru
activ
therefor
favipiravir
posit
valuabl
antiinfluenza
drug
broad
spectrum
antirna
drug
list
tabl
favipiravir
use
human
therapi
ebola
hemorrhag
fever
bai
et
al
jacob
et
al
sissoko
et
al
lassa
fever
raab
et
al
noroviru
rui
et
al
rabi
baker
sft
yasukawa
treatment
use
emerg
use
set
clinic
trial
addit
combin
therapi
favipiravir
exist
therapi
also
option
favipiravir
oseltamivir
combin
therapi
show
acceler
clinic
recoveri
compar
oseltamivir
monotherapi
sever
influenza
china
cao
wang
et
al
antivir
activ
ec
favipiravir
influenza
ebola
virus
differ
rang
medium
without
adenosin
guanosin
respect
furuta
et
al
oestereich
et
al
addit
x
ec
adenin
guanin
adenosin
guanosin
inosin
assay
medium
abolish
antiinfluenza
viru
activ
favipiravir
furuta
et
al
intracellular
concentr
atp
mm
variou
tissu
bei
newsholm
suggest
favipiravir
may
need
higher
concentr
vivo
pharmacokinet
valu
favipiravir
maximum
drug
concentr
cmax
area
curv
auc
maximum
drug
concentr
time
tmax
halflif
period
h
h
respect
avigan
tablet
mg
packag
insert
approv
favipiravir
dose
influenza
japan
mg
twice
day
day
follow
mg
twice
day
day
dose
ebloa
viru
infect
mg
first
day
mgday
day
antivir
concentr
favipiravir
influenza
achiev
lung
epithelium
diffus
blood
case
ebola
viru
infect
direct
perfus
blood
reach
target
tissu
vascular
endotheli
cell
hematopoiet
cell
hepatocyt
differ
two
factor
antivir
concentr
target
cell
appear
significantli
reflect
dosag
intraven
prepar
prepar
improv
oral
administr
favipiravir
favipiravir
inhibit
viral
rdrp
termin
elong
incorpor
site
chain
termin
jin
smith
rajwanshi
kim
deval
sangawa
et
al
favipiravir
function
purin
analogu
expect
chemic
structur
incorpor
instead
guanosin
adenosin
favipiravir
termin
elong
incorpor
singl
favipiravir
molecul
sangawa
et
al
incorpor
two
consecut
favipiravir
molecul
jin
et
al
synthesi
complementari
viral
rna
strand
complet
contrast
antirna
viru
drug
ribavirin
incorpor
replic
strand
elong
accumul
mismatch
nucleotid
incorpor
site
base
pair
ribavirin
complementari
strand
replic
transcript
translat
rna
strand
caus
mismatch
base
pair
product
nonfunct
protein
loss
viral
infect
accumul
mutat
mismatch
nucleotid
caus
replic
virus
lose
replic
capabl
known
lethal
mutagenesi
vignuzzi
stone
andino
shown
fig
number
mutat
limit
infecti
virus
mutat
viral
rdrp
affect
ribavirin
incorpor
produc
drugresist
virus
select
presenc
ribavirin
favipiravir
treatment
increas
frequenc
transit
delang
et
al
goldhil
et
al
vanderlinden
et
al
transvers
baranovich
et
al
viral
genom
mutat
hypothes
caus
favipiravir
result
lethal
mutagenesi
baranovich
et
al
delang
et
al
goldhil
et
al
vanderlinden
et
al
observ
transit
influenza
viru
polioviru
cultur
treat
favipiravir
assess
frequenc
unabl
compar
transit
rate
proper
antivir
agent
similar
mechan
control
daikoku
yoshida
okuda
shiraki
ribavirin
known
caus
lethal
mutagenesi
shown
fig
ribavirin
incorpor
elong
rna
strand
result
product
multipl
mismatch
lead
lethal
mutagenesi
vignuzzi
et
al
favipiravir
inhibit
rna
synthesi
chain
termin
inhibitori
mechan
consist
explain
observ
report
mechan
similar
ribavirin
describ
rtp
higher
affin
rdrp
influenza
viru
gtp
function
chain
termin
jin
et
al
sangawa
et
al
favipiravirrtp
ribavirin
tp
inhibit
rdrp
activ
dosedepend
manner
inhibitori
concentr
ic
respect
furuta
et
al
rdrp
activ
determin
measur
incorpor
label
gtp
elong
rna
strand
favipiravirrtp
higher
affin
rdrp
gtp
incorpor
favipiravirrtp
stop
elong
rna
strand
incorpor
termin
prevent
incorpor
radioact
thu
favipiravirrtp
exhibit
high
inhibitori
activ
low
ic
hand
ribavirin
induc
competit
inhibit
gtp
incorpor
result
mismatch
mutat
strand
continu
elong
incorpor
label
gtp
without
stop
incorpor
site
thu
ribavirin
high
ic
valu
rna
strand
elong
incorpor
radiolabel
gtp
therefor
abil
inhibit
enzym
activ
becom
weaker
display
higher
ic
valu
favipiravir
furthermor
mark
decreas
amount
viral
genom
observ
favipiravirtr
cultur
compar
ribavirintr
cultur
vanderlinden
et
al
favipiravir
incorpor
viral
genom
termin
elong
result
shorter
genom
size
mark
loss
viral
genom
favipiravirtr
cultur
rochapereira
et
al
vanderlinden
et
al
observ
consist
explain
chain
termin
induc
favipiravir
proofread
activ
mediat
enzym
exonucleas
herpesviru
dna
polymeras
remov
termin
mismatch
base
correct
base
pair
elong
process
viral
rdrp
lack
proofread
activ
unabl
complet
elong
step
favipiravirrtp
incorpor
chain
termin
coronaviru
report
express
proofread
function
among
rna
virus
smith
blanc
surdel
vignuzzi
denison
acyclovir
caus
chain
termin
incorpor
site
elong
herp
simplex
viru
varicellazost
viru
dna
prevent
viral
dna
synthesi
howev
incorpor
acyclovir
remov
proofread
activ
viral
dna
polymeras
viral
dna
elong
continu
therefor
sequenc
contain
guanosin
homopolymer
string
gstring
genom
target
incorpor
remov
acyclovir
incorpor
guanosin
follow
repeat
correct
proofread
machineri
creat
hot
spot
mutat
gstring
laboratori
clinic
acyclovirresist
isol
akahoshi
et
al
daikoku
et
al
ida
et
al
shimada
et
al
talarico
phelp
biron
penciclovir
famciclovir
ganciclovir
valganciclovir
guanosin
analogu
function
antiherp
simplex
viru
varicellazost
viru
agent
anticytomegaloviru
agent
respect
mechan
similar
acyclovir
induc
mutat
hot
spot
gstring
compound
prevent
elong
incorpor
site
incorpor
elong
paus
normal
nucleotid
incorpor
site
therefor
mutat
associ
proofread
occur
gstring
differ
mode
chain
termin
proofread
activ
caus
lower
mutat
frequenc
subject
treat
penciclovir
ganciclovir
subject
treat
acyclovir
favipiravir
induc
mismatch
mutagen
favipiravir
allow
elong
incorpor
elong
rna
strand
induc
mismatch
favipiravirincorpor
site
new
complementari
strand
possibl
inconsist
mechan
favipiravir
chain
termin
thu
increas
mutat
rate
observ
respons
favipiravir
treatment
unlik
due
incorpor
favipiravir
viral
rna
follow
elong
similar
ribavirin
acyclovir
fig
favipiravir
unlik
induc
mismatch
upon
incorpor
rna
strand
transit
influenza
viru
genom
increas
rate
transit
mutat
observ
favipiravir
treatment
presum
due
bias
nucleotid
pool
induc
increas
level
favipiravirrtp
properti
viral
rdrp
bias
nucleotid
pool
major
factor
promot
polymeraseinduc
mutat
synthesi
wheeler
rajagop
mathew
influenza
rdrp
complex
compos
pa
requir
four
nucleotid
atp
gtp
ctp
utp
substrat
rna
synthesi
influenza
rdrp
incorpor
mismatch
nucleotid
primerextensionbas
misincorpor
assay
presenc
complet
bias
nucleotid
pool
consist
three
nucleotid
instead
four
nucleotid
aggarw
bradeltretheway
takimoto
dewhurst
kim
even
one
four
nucleotid
miss
absenc
compens
nucleotid
rna
strand
continu
elong
caus
mismatch
therefor
even
absenc
mutagen
mismatch
occur
rna
synthesi
bias
nucleotid
pool
condit
mutagen
present
influenza
rdrp
display
significantli
higher
fidel
human
immunodefici
revers
transcriptas
rna
polymeras
equival
higher
fidel
murin
leukemia
viru
revers
transcriptas
aggarw
et
al
mutat
frequenc
influenza
rdrp
nucleotid
wildtyp
viru
fig
chain
termin
lethal
mutagenesi
chain
termin
favipiravir
convert
favipiravirrtp
incorpor
elong
rna
strand
chain
elong
stop
site
favipiravir
incorpor
elong
proceed
favipiravir
function
chain
termin
rnafavipiravir
complex
repair
proofread
enzym
would
dispos
unnecessari
rna
result
extinct
viral
genom
rochapereira
et
al
vanderlinden
et
al
b
lethal
mutagenesi
ribavirin
incorpor
elong
rna
strand
viral
rdrp
continu
elong
complet
next
rna
strand
multipl
ribavirin
incorpor
site
incorpor
ribavirin
serv
mrna
viral
protein
synthesi
incorpor
ribavirin
viral
rna
caus
mismatch
base
pair
transit
mutat
translat
rna
caus
mutat
amino
acid
sequenc
protein
result
impair
function
viral
protein
impair
function
fail
replic
produc
infecti
viral
particl
viral
infect
ceas
thu
lethal
mutagenesi
termin
viral
infect
differ
mechan
chain
termin
cheung
et
al
nucleotid
deduc
sequenc
clone
averag
base
databas
drake
valu
much
larger
herpesviru
dna
polymeras
proofread
activ
level
per
nucleotid
lee
et
al
substitut
per
site
per
year
mcgeoch
dolan
ralph
result
indic
low
fidel
rdrp
activ
influenza
lack
proofread
activ
jurkat
cell
expos
guanosin
h
show
increas
gtp
pool
control
decreas
atp
control
batiuk
schnizleinbick
plotkin
dagher
thu
intracellular
condit
bias
nucleotid
pool
alon
suffici
increas
ratio
mismatch
transit
mutat
without
treatment
mutagen
ribavirin
ribavirin
reduc
gtp
level
inhibit
inosin
monophosph
dehydrogenas
favipiravir
littl
effect
gtp
level
furuta
et
al
vanderlinden
et
al
guanosin
analogu
extracellular
favipiravir
may
bia
nucleotid
pool
favipiravirrtp
compet
gtp
atp
result
increas
transit
mutat
although
data
avail
support
specul
observ
increas
transit
frequenc
presum
due
low
fidel
rdrp
influenza
viru
misincorpor
nucleotid
bias
nucleotid
pool
favipiravirtr
cell
favipiravir
chain
termin
without
direct
mutagen
activ
increas
number
mismatch
genom
due
induct
bias
nucleotid
pool
favipiravirtr
cultur
isol
herp
simplex
viru
resist
acyclovir
phosphonoacet
acid
foscarnet
varicellazost
viru
resist
acyclovir
penciclovir
foscarnet
vidarabin
cytomegaloviru
resist
ganciclovir
foscarnet
mizoribin
cultur
viru
presenc
antivir
agent
ida
et
al
ida
et
al
kamiyama
kurokawa
shiraki
kuramoto
et
al
kurosaki
et
al
miwa
et
al
mori
et
al
shiraki
ogino
yamanishi
takahashi
resist
virus
replac
viru
popul
presenc
drug
vitro
patient
emerg
replac
resist
strain
occur
herpet
lesion
immunocompromis
individu
lesion
viral
growth
treat
least
one
two
week
oseltamiviror
baloxavir
marboxil
baloxavir
resist
viru
emerg
patient
season
influenza
treatment
isol
viru
replac
resist
viru
subsequ
new
infect
resist
viru
confirm
therefor
investig
possibl
favipiravirresist
viru
appear
cultur
cell
influenza
viru
grow
presenc
favipiravir
prolifer
viru
replac
resist
viru
tri
isol
favipiravirresist
influenza
viru
polioviru
cm
flask
respect
independ
cultur
presenc
increas
concentr
favipiravir
month
resist
viru
isol
daikoku
et
al
daikoku
et
al
decid
deni
possibl
replac
resist
viru
spontan
mutat
rate
influenza
viru
rdrp
complex
polioviru
rdrp
approxim
cheung
et
al
drake
gubareva
fri
titer
influenza
viru
polioviru
cultur
reach
approxim
infecti
viral
particlesml
ml
media
cm
flask
genom
contain
approxim
base
pair
respect
stochast
indic
alter
per
nucleotid
genom
therefor
everi
type
mutant
gener
replic
continu
cultiv
month
might
increas
favipiravirresist
viru
popul
favipiravir
induc
mutat
frequent
natur
process
mutant
resist
favipiravir
isol
easili
cultur
replac
favipiravirresist
mutant
isol
suscept
variant
influenza
viru
polioviru
cultur
treat
favipiravir
month
identifi
nucleotid
substitut
mutat
rdrp
gene
mutat
relat
resist
mutat
common
favipiravir
daikoku
et
al
daikoku
et
al
therefor
theoret
resist
mutant
gener
unabl
replic
replic
reduc
fidel
replac
entir
viru
popul
favipiravirresist
mutant
replic
artifici
gener
clone
becom
domin
among
entir
viru
popul
grow
presenc
favipiravir
abdelnabi
et
al
delang
et
al
goldhil
et
al
result
consist
absenc
resist
viru
entir
viru
popul
treat
favipiravir
mani
laboratori
attempt
isol
favipiravirresist
influenza
virus
success
recent
mutant
influenza
viru
goldhil
et
al
chikungunya
viru
abdelnabi
et
al
delang
et
al
less
suscept
favipiravir
report
mutat
sequenc
virus
detect
cultur
treat
favipiravir
reverseengin
virus
show
favipiravir
resist
alter
rdrp
activ
relat
fidel
reduc
growth
properti
mutat
motif
f
gene
observ
viru
popul
cultiv
presenc
favipiravir
viru
mutat
creat
revers
engin
confirm
favipiravirresist
viru
howev
viru
artifici
produc
grown
clone
consid
domin
viru
cultur
mutat
show
reduc
polymeras
activ
acquir
pa
replic
acquisit
addit
pa
mutat
restor
polymeras
activ
favipiravir
resist
goldhil
et
al
mutat
motif
rdrp
chikungunya
viru
less
suscept
favipiravir
display
reduc
growth
properti
acquir
addit
mutat
helicaseproteas
passag
absenc
favipiravir
delang
et
al
correspond
ktor
substitut
chikungunya
viru
mutat
introduc
coxsackieviru
rdrp
engin
viru
mutat
rdrp
nonviabl
viru
abdelnabi
et
al
replic
compet
variant
restor
addit
acquisit
substitut
rdrp
variant
viru
mutat
suscept
favipiravir
exhibit
lower
fidel
wildtyp
viru
common
featur
less
suscept
virus
high
fidel
rdrp
may
distinguish
favipiravirrtp
gtp
replic
presenc
favipiravir
avoid
incorpor
favipiravirrtp
sinc
prolif
abil
high
clone
less
suscept
favipiravir
grow
well
alon
viabl
addit
alter
modul
rdrp
activ
restor
replic
capabl
suscept
favipiravir
abdelnabi
et
al
delang
et
al
goldhil
et
al
favipiravirresist
mutant
influenza
viru
creat
reverseengin
replic
clone
reduc
growth
properti
therefor
viru
unlik
replac
entir
grow
viru
popul
produc
favipiravir
treatment
observ
mani
laboratori
two
highli
pathogen
influenza
virus
chicken
muscovi
duck
one
influenza
viru
ruddi
turnston
two
swine
origin
influenza
virus
possess
mutat
may
result
highfidel
rdrp
confirm
cheung
et
al
thu
research
consid
possibl
chang
suscept
favipiravir
type
influenza
virus
caus
pandem
antivir
suscept
examin
pair
influenza
virus
isol
patient
administr
favipiravir
phase
clinic
trial
virus
display
reduc
suscept
favipiravir
although
two
pair
isol
one
pair
isol
one
pair
b
virus
possess
amino
acid
substitut
rdrp
subunit
pa
favipiravir
administr
takashita
et
al
amino
acid
substitut
rdrp
noth
suscept
favipiravir
seem
occur
regardless
favipiravir
treatment
trial
limit
clinic
studi
assess
emerg
favipiravirresist
viru
appear
oseltamivir
baloxavir
resist
might
observ
clinic
trial
influenza
treatment
oseltamivir
baloxavir
similar
number
patient
describ
section
lack
emerg
replac
resist
virus
favipiravir
treatment
vitro
human
indic
effect
favipiravir
expect
maintain
begin
end
influenza
pandem
patient
could
treat
effect
caus
death
sever
infect
may
liver
failur
renal
failur
respiratori
failur
enceph
ebola
viru
infect
seem
difficult
patient
chanc
infect
fever
infect
amount
viru
use
indic
time
infect
sissoko
et
al
renal
function
repres
creatinin
level
found
import
factor
prognosi
factor
determin
surviv
death
rate
favipiravir
treatment
seem
residu
organ
function
start
treatment
fatal
infect
caus
cytotox
rna
virus
residu
function
necessari
recoveri
organ
estim
indic
criteria
organ
transplant
one
criteria
lung
function
lung
transplant
patient
forc
expiratori
volum
less
maurer
frost
estenn
higenbottam
glanvil
concern
renal
function
hemodialysi
start
renal
function
fall
death
occur
within
one
sever
week
dialysi
stop
nation
kidney
foundat
concern
liver
function
donor
liver
left
residu
liver
volum
least
total
liver
volum
ensur
hepat
graft
excel
result
low
donor
morbid
pomfret
pomposelli
jenkin
import
begin
treatment
lose
recover
function
target
organ
sinc
pneumonia
main
caus
death
influenza
may
progress
extent
even
start
treatment
time
ill
onset
oseltamivir
treatment
avian
influenza
viru
infect
day
day
time
ill
onset
develop
acut
respiratori
distress
syndrom
ard
day
day
li
et
al
indic
import
earli
diagnosi
treatment
ebola
viru
infect
direct
caus
death
relat
bleed
hemorrhag
shock
degre
liver
dysfunct
renal
dysfunct
seem
relat
surviv
death
rate
seen
anim
model
treat
favipiravir
oestereich
et
al
sft
mainli
caus
tick
bite
develop
fever
liver
renal
dysfunct
sft
may
caus
death
yamaguchi
prefectur
first
patient
found
japan
dermatologist
examin
tick
bite
monitor
develop
sft
enabl
earli
treatment
favipiravir
develop
antiinfluenza
drug
efficaci
sever
infect
caus
high
viral
load
approv
antiinfluenza
drug
japan
favipiravir
similar
mechan
action
antiherpesviru
drug
acyclovir
properti
produc
resist
viru
favipiravir
contraind
pregnant
women
due
teratogen
embryotox
anim
subsequ
stockpil
dose
million
peopl
perform
countermeasur
novel
influenza
japan
favipiravir
use
treat
lethal
infect
human
efficaci
confirm
wide
rang
anim
model
lethal
rna
infect
sever
human
rna
infect
sporad
number
case
limit
patient
infect
favipiravir
use
urgent
lifesav
purpos
standard
effect
treatment
rather
show
efficaci
clinic
trial
perform
compar
histor
control
patient
patient
treat
favipiravir
ebola
viru
infect
bai
et
al
jacob
et
al
sissoko
et
al
sft
yasukawa
subsequ
favipiravir
submit
addit
indic
base
clinic
trial
sft
japan
establish
placebo
group
receiv
effect
drug
lethal
anim
model
challeng
problem
confirm
efficaci
favipiravir
random
placebocontrol
trial
exampl
situat
pep
human
immunodefici
viru
perform
protect
needl
stick
occup
exposur
without
placebo
becom
standard
procedur
guidelin
due
prophylact
effect
result
mani
year
implement
kuhar
et
al
sinc
children
die
avian
influenza
hong
kong
ku
chan
concern
express
novel
influenza
pandem
influenza
pandem
consist
global
outbreak
influenza
viru
occur
although
pathogen
viru
milder
caus
pandem
health
problem
although
immun
influenza
among
elderli
caus
health
problem
young
peopl
substanti
social
impact
next
candid
pandem
influenza
avian
influenza
caus
sever
infect
pneumonia
due
prolong
viral
replic
caus
lack
immun
tropism
pulmonari
epithelium
high
mortal
rate
lai
et
al
li
et
al
shinya
et
al
abil
predict
whether
pandem
occur
remain
challeng
necessari
strategi
appear
stockpil
vaccin
antiinfluenza
drug
novel
influenza
strain
cope
pandem
specif
featur
mechan
action
favipiravir
fact
favipiravir
alon
produc
resist
virus
among
antiinfluenza
drug
suggest
expect
play
central
role
among
antiinfluenza
drug
treatment
lethal
influenza
pandem
review
help
clinician
scientist
policymak
consid
prepared
strategi
avian
influenza
pandem
use
antiinfluenza
drug
favipiravir
prophylaxi
treatment
well
prevent
vaccin
ks
report
receipt
consult
fee
maruho
co
ltd
lectur
fee
maruho
co
ltd
msd
novarti
research
fund
maruho
co
ltd
msd
japan
blood
product
organ
payment
sent
institut
favipiravir
elsevi
languag
edit
edit
english
languag
manuscript
studi
support
part
jsp
kakenhi
grant
number
ministri
educ
cultur
sport
scienc
technolog
japan
joint
research
project
toyama
chemic
co
ltd
